Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.42 |
| ▸ | HTR2B | P41595 | 8/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | HRH2 | P25021 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523661 | 0.83 | HTR2C (0.44) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL2523419 | 0.83 | CYP4F2 (0.51) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL3069648 | 0.81 | ADRA2A (0.42) | HTR2CHTR2BHTR2AADRA2AADRA2B | |
| SCHEMBL27721851 | 0.81 | HTR2C (0.40) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL3065052 | 0.80 | MAPT (0.41) | GAATSHRLMNAALDH1A1CYP2D6 | |
| SCHEMBL7623243 | 0.79 | MAPT (0.49) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL4879810 | 0.79 | ALDH1A1 (0.56) | GAALMNAALDH1A1CYP2D6MAPT | |
| SCHEMBL2523355 | 0.78 | GAA (0.45) | HTR2CHTR2BHTR2AADRA2AADRA2B | |
| SCHEMBL27726597 | 0.77 | HTR2C (0.41) | HTR2CHTR2BHTR2AADRB2HTR1A | |
| SCHEMBL4523312 | 0.77 | GAA (0.41) | HTR2CHTR2AADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2872515-B1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-08 | — | — | EP | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| WO-2014009509-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN R&D IRELAND (IE) | 2014-01-16 | — | — | WO | disclosed |
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| CN-101351455-A | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | HTR2C 1855/4885HTR2B 2622/4885HTR2A 2135/4885 |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | HTR2C 1855/4885HTR2B 2622/4885HTR2A 2135/4885 |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | HTR2C 4333/4885HTR2B 4408/4885HTR2A 4683/4885 |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | HTR2C 1855/4885HTR2B 2622/4885HTR2A 2135/4885 |
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | HTR2C 1855/4885HTR2B 2622/4885HTR2A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.